Alba Toll
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Alba Toll has a total of 190 co-authors. Here are the top co-authors by number of shared publications:
- Daniel Bergé
Institut de Neuropsiquiatria i Adiccions (INAD), Parc de Salut Mar, Barcelona, Spain; Fundació Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain; Centro de Investigación Biomédica en Red, Área de Salud Mental (CIBERSAM), Spain
5 shared publications - Anna Mané
Hospital del Mar
3 shared publications - Eduard Vieta
Hospital Clínic de Barcelona
3 shared publications - Laura Martínez-Sadurní
Hospital del Mar Research Institute, Barcelona, Spain
3 shared publications - Manuel J. Cuesta
Department of Psychiatry, Hospital Universitario de Navarra, Pamplona, Spain
3 shared publications - Albert Martínez-Pinteño
Fundació de Recerca Clínic Barcelona-Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), 08036 Barcelona, Spain
2 shared publications
Latest Publications
- Open Access
- 6 November 2026
- Published by Royal College of Psychiatrists in BJPsych Open
- Vol. 12 (6) , e287
Impact of long-acting olanzapine shortage on clinical outcomes: retrospective cohort from a Spanish mental health day hospital
Summary: In 2025, a nationwide shortage of long-acting injectable olanzapine (Zypadhera) forced treatment changes in patients at the Mental Health Day Hospital of Mataró (Spain). We retrospectively identified 23 consecutive patients receiving Zypadhera and recorded subsequent therapeutic alternatives, relapse, service disengagement and re-initiation of Zypadhera. Relapse or disengagement occurred in 39% of patients, with significantly fewer events observed among patients switched to oral olanzapine compared with long-acting injectable aripiprazole (log-rank P = 0.008). Female sex, younger age and tobacco use were associated with increased risk. This study highlights the need for contingency planning and careful selection of alternatives.
- 6 November 2026
- Published by Royal College of Psychiatrists in BJPsych Open
- Vol. 12 (6) , e287
Open AccessImpact of long-acting olanzapine shortage on clinical outcomes: retrospective cohort from a Spanish mental health day hospital
Summary: In 2025, a nationwide shortage of long-acting injectable olanzapine (Zypadhera) forced treatment changes in patients at the Mental Health Day Hospital of Mataró (Spain). We retrospectively identified 23 consecutive patients receiving Zypadhera and recorded subsequent therapeutic alternatives, relapse, service disengagement and re-initiation of Zypadhera. Relapse or disengagement occurred in 39% of patients, with significantly fewer events observed among patients switched to oral olanzapine compared with long-acting injectable aripiprazole (log-rank P = 0.008). Female sex, younger age and tobacco use were associated with increased risk. This study highlights the need for contingency planning and careful selection of alternatives.
- 26 September 2026
- Published by Elsevier in The European Journal of Psychiatry
- Vol. 40 (4)
Age modifies the association between sex and involuntary admission in psychotic disorders: a retrospective cross-sectional study
- 26 September 2026
- Published by Elsevier in The European Journal of Psychiatry
- Vol. 40 (4)
Age modifies the association between sex and involuntary admission in psychotic disorders: a retrospective cross-sectional study
- Open Access
Not all migrants are the same: geographic origin and long-term outcomes after first-episode psychosis—a retrospective cohort study
Background: Migration is a well-established risk factor for psychosis, yet limited research has examined long-term clinical trajectories following first-episode psychosis (FEP) in migrant populations within Southern European settings. This study investigates how country of origin and time since migration influence psychiatric outcomes in a naturalistic FEP cohort. Methods: A 5-year longitudinal study was conducted on 184 patients with FEP attending the Early Intervention Service from Hospital Universitari de Mataró. Patients were grouped by geographic origin (Spanish, Latin American, Maghrebi, Sub-Saharan) and migration recency (≤5 years vs . >5 years). Primary outcomes included treatment adherence, use of long-acting injectable (LAI) antipsychotics, relapse, and service disengagement. Logistic regression and survival analyses were used to identify associations. Results: Maghrebi origin was associated with lower treatment adherence (OR = 0.32, 95% CI [0.12–0.89], p = 0.030). In time-to-event analyses, Maghrebi patients showed a higher hazard of service disengagement compared with Spanish-born patients (HR = 2.42, 95% CI [1.10–5.34], p = 0. 028). Recent migrants (≤5 years in Spain) also had a significantly increased hazard of disengagement (HR = 2.89, 95% CI [1.30–6.40], p = 0.009). Sub-Saharan origin was strongly associated with earlier initiation of long-acting injectable antipsychotics (HR = 3.40, 95% CI [1.58–7.32], p = 0.002), alongside higher overall odds of LAI use. No significant differences were observed in relapse rates across groups. Conclusions: Both migrant origin and recent arrival were associated with differences in psychiatric care trajectories following FEP. These findings highlight the need to consider adaptation of treatment approaches for migrant populations according to their origin and migration context in order to improve long-term outcomes.
Open AccessNot all migrants are the same: geographic origin and long-term outcomes after first-episode psychosis—a retrospective cohort study
Background: Migration is a well-established risk factor for psychosis, yet limited research has examined long-term clinical trajectories following first-episode psychosis (FEP) in migrant populations within Southern European settings. This study investigates how country of origin and time since migration influence psychiatric outcomes in a naturalistic FEP cohort. Methods: A 5-year longitudinal study was conducted on 184 patients with FEP attending the Early Intervention Service from Hospital Universitari de Mataró. Patients were grouped by geographic origin (Spanish, Latin American, Maghrebi, Sub-Saharan) and migration recency (≤5 years vs . >5 years). Primary outcomes included treatment adherence, use of long-acting injectable (LAI) antipsychotics, relapse, and service disengagement. Logistic regression and survival analyses were used to identify associations. Results: Maghrebi origin was associated with lower treatment adherence (OR = 0.32, 95% CI [0.12–0.89], p = 0.030). In time-to-event analyses, Maghrebi patients showed a higher hazard of service disengagement compared with Spanish-born patients (HR = 2.42, 95% CI [1.10–5.34], p = 0. 028). Recent migrants (≤5 years in Spain) also had a significantly increased hazard of disengagement (HR = 2.89, 95% CI [1.30–6.40], p = 0.009). Sub-Saharan origin was strongly associated with earlier initiation of long-acting injectable antipsychotics (HR = 3.40, 95% CI [1.58–7.32], p = 0.002), alongside higher overall odds of LAI use. No significant differences were observed in relapse rates across groups. Conclusions: Both migrant origin and recent arrival were associated with differences in psychiatric care trajectories following FEP. These findings highlight the need to consider adaptation of treatment approaches for migrant populations according to their origin and migration context in order to improve long-term outcomes.
- 9 May 2026
- Published by Springer Nature in Archives of Women's Mental Health
- Vol. 29 (3) , 74
Women with first-episode psychosis: diagnostic stability and clinical trajectories
Purpose The aim of this study was to assess the influence of sex on diagnostic stability in first-episode psychosis during the first year of follow-up. Methods This was a prospective, observational study of 256 patients with FEP, of whom 188 (73.4%) completed the 1-year follow-up. Patients were consecutively recruited at a specialized early intervention program. Comprehensive psychiatric evaluations and the Structured Clinical Interview for DSM-IV-TR Axis I disorders were performed at baseline and follow-up. Diagnoses were grouped into affective and non-affective psychoses. Univariate and multivariate logistic regression analyses were conducted to identify predictors of diagnostic shift, with a particular focus on sex. Results At one-year follow-up, 48.9% of patients experienced some form of diagnostic change. Specifically, 14.4% shifted from non-affective to affective psychosis. Female sex was the only independent predictor of diagnostic shift (OR = 0.30; 95% CI = 0.10–0.87; p = 0.027). No other clinical or demographic variables were significantly associated with diagnostic change. Conclusion Female FEP patients were significantly more likely to experience a diagnostic shift toward affective psychosis during the first year of follow-up. These findings highlight the importance of considering sex differences in clinical presentation at illness onset to improve diagnostic accuracy, optimize treatment strategies, and enhance long-term outcomes.
- 9 May 2026
- Published by Springer Nature in Archives of Women's Mental Health
- Vol. 29 (3) , 74
Women with first-episode psychosis: diagnostic stability and clinical trajectories
Purpose The aim of this study was to assess the influence of sex on diagnostic stability in first-episode psychosis during the first year of follow-up. Methods This was a prospective, observational study of 256 patients with FEP, of whom 188 (73.4%) completed the 1-year follow-up. Patients were consecutively recruited at a specialized early intervention program. Comprehensive psychiatric evaluations and the Structured Clinical Interview for DSM-IV-TR Axis I disorders were performed at baseline and follow-up. Diagnoses were grouped into affective and non-affective psychoses. Univariate and multivariate logistic regression analyses were conducted to identify predictors of diagnostic shift, with a particular focus on sex. Results At one-year follow-up, 48.9% of patients experienced some form of diagnostic change. Specifically, 14.4% shifted from non-affective to affective psychosis. Female sex was the only independent predictor of diagnostic shift (OR = 0.30; 95% CI = 0.10–0.87; p = 0.027). No other clinical or demographic variables were significantly associated with diagnostic change. Conclusion Female FEP patients were significantly more likely to experience a diagnostic shift toward affective psychosis during the first year of follow-up. These findings highlight the importance of considering sex differences in clinical presentation at illness onset to improve diagnostic accuracy, optimize treatment strategies, and enhance long-term outcomes.
- Open Access
- 31 March 2026
- Published by Springer Nature in Translational Psychiatry
- Vol. 16 (1) , 220
Bioenergetic and early treatment response stratification (BIOERES): a two-variable prognostic model for early identification of treatment-resistance schizophrenia
Approximately one-third of patients with first-episode schizophrenia-spectrum disorders develop treatment-resistant schizophrenia (TRS) within five years, yet reliable early predictors remain lacking. Routine cerebrospinal fluid (CSF) biomarkers may offer insights into TRS pathophysiology and enable early prognostic stratification. In this longitudinal study, we examined whether baseline CSF parameters—total protein, glucose, and lactate dehydrogenase (LDH)—predicted TRS, defined according to TRRIP consensus criteria and clozapine use. Forty-four patients with first-episode schizophrenia spectrum disorders underwent lumbar puncture during index hospitalization and were followed clinically for five years at the Mataró Mental Health Care Centre. TRS status was confirmed through detailed electronic health record review. Thirteen patients (29.5%) met TRS criteria. At baseline, these individuals had significantly lower CSF LDH concentrations compared to non-TRS patients (p = 0.014), while glucose and protein levels showed no significant differences. In adjusted logistic regression models, lower LDH remained independently associated with TRS (OR = 0.043, p = 0.031). A combined model incorporating LDH and early antipsychotic response achieved an AUC of 0.86, outperforming LDH alone (AUC = 0.73), and demonstrating good discriminative accuracy. Lower baseline CSF LDH concentrations predicted treatment resistance at five years, especially when combined with poor early antipsychotic response. This two-variable prognostic model—BIOERES (Bioenergetic and Early Response Stratification)—may facilitate early identification of high-risk patients and support personalized treatment strategies. Validation in larger, independent cohorts is needed.
- 31 March 2026
- Published by Springer Nature in Translational Psychiatry
- Vol. 16 (1) , 220
Open AccessBioenergetic and early treatment response stratification (BIOERES): a two-variable prognostic model for early identification of treatment-resistance schizophrenia
Approximately one-third of patients with first-episode schizophrenia-spectrum disorders develop treatment-resistant schizophrenia (TRS) within five years, yet reliable early predictors remain lacking. Routine cerebrospinal fluid (CSF) biomarkers may offer insights into TRS pathophysiology and enable early prognostic stratification. In this longitudinal study, we examined whether baseline CSF parameters—total protein, glucose, and lactate dehydrogenase (LDH)—predicted TRS, defined according to TRRIP consensus criteria and clozapine use. Forty-four patients with first-episode schizophrenia spectrum disorders underwent lumbar puncture during index hospitalization and were followed clinically for five years at the Mataró Mental Health Care Centre. TRS status was confirmed through detailed electronic health record review. Thirteen patients (29.5%) met TRS criteria. At baseline, these individuals had significantly lower CSF LDH concentrations compared to non-TRS patients (p = 0.014), while glucose and protein levels showed no significant differences. In adjusted logistic regression models, lower LDH remained independently associated with TRS (OR = 0.043, p = 0.031). A combined model incorporating LDH and early antipsychotic response achieved an AUC of 0.86, outperforming LDH alone (AUC = 0.73), and demonstrating good discriminative accuracy. Lower baseline CSF LDH concentrations predicted treatment resistance at five years, especially when combined with poor early antipsychotic response. This two-variable prognostic model—BIOERES (Bioenergetic and Early Response Stratification)—may facilitate early identification of high-risk patients and support personalized treatment strategies. Validation in larger, independent cohorts is needed.
- Open Access
- 12 March 2026
- Published by Elsevier in SSRN Electronic Journal
Neutrophil to Lymphocyte Ratio and Clozapine Response in Treatment Resistant Schizophrenia: An Individual Participant Data Meta-Analysis
Background: Treatment-resistant schizophrenia (TRS) affects one in three people with schizophrenia. Clozapine remains the only approved treatment, yet its mechanism of action is poorly understood. Converging evidence implicates immune dysregulation in TRS and suggests clozapine exerts unique immunomodulatory effects, but large-scale clinical data linking immune biomarkers – such as the neutrophil-to-lymphocyte ratio (NLR) – to clozapine response are lacking. We tested whether higher baseline NLR predicts clozapine response and whether NLR normalizes with effective treatment.Methods: We collected individual participant data – through systematic review, data repositories, and expert consultation – to conduct a meta-analysis of clozapine trials (8–24 weeks) in adults with TRS. All datasets underwent a standardized analytic pipeline. Primary analyses were logistic regression of baseline NLR predicting response (≥20% symptom improvement) and correlation between change in NLR and change in symptoms. Study-level estimates were pooled using fixed-effects meta-analysis. Meta-regressions examined sex, age, race, baseline severity, and baseline NLR. People with lived experience were involved in the interpretation of the results.Findings: Ten trials contributed 593 participants (236 [39·8%] female; mean age 37·5 years [SD 3·8]; 281 [47·4%] African ancestry). Mean baseline PANSS total was 90·1 (SD 16·2), baseline NLR 1·66 (SD 0·34), and pooled response rate 48·1%. Higher baseline NLR predicted clozapine response (OR=1·26; 95% CI 1·02–1·55; p=0·03; I2=0%). Female sex was independently associated with response (OR=1·66; 95% CI 1·14–2·41; p=0·008). NLR decreased as symptoms improved (r=−0·11; 95% CI −0·19 to −0·03; p=0·01; I2=0%). No study-level covariates moderated either association and there was no evidence of publication bias.Interpretation: Clozapine may exert its antipsychotic effects in TRS partly through normalisation of a heightened inflammatory state. Pre-treatment NLR, already routinely available from mandatory baseline blood work, could support earlier and more targeted clozapine initiation and inform development of novel anti-inflammatory strategies for TRS.PanelResearch in contextEvidence before this studyConverging evidence suggests that treatment resistant schizophrenia (TRS) is characterized by immune dysregulation and altered neuroimmune activity. Clozapine is the only drug indicated for TRS, and it is associated with unique immune mediated off target effects (e.g., benign fever, myocarditis…) and animal model data indicating immunomodulatory effects. Small studies suggest that immune effects may mediate clozapine unique antipsychotic properties in TRS, but large-scale clinical data is lacking.Added value of this studyIn this large-scale individual participant data meta-analysis we show that a higher inflammation state indicated by greater neutrophil to lymphocyte ratio (NLR) is associated with greater odds of responding to clozapine and that as symptoms improve the NLR normalizes.
- 12 March 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessNeutrophil to Lymphocyte Ratio and Clozapine Response in Treatment Resistant Schizophrenia: An Individual Participant Data Meta-Analysis
Background: Treatment-resistant schizophrenia (TRS) affects one in three people with schizophrenia. Clozapine remains the only approved treatment, yet its mechanism of action is poorly understood. Converging evidence implicates immune dysregulation in TRS and suggests clozapine exerts unique immunomodulatory effects, but large-scale clinical data linking immune biomarkers – such as the neutrophil-to-lymphocyte ratio (NLR) – to clozapine response are lacking. We tested whether higher baseline NLR predicts clozapine response and whether NLR normalizes with effective treatment.Methods: We collected individual participant data – through systematic review, data repositories, and expert consultation – to conduct a meta-analysis of clozapine trials (8–24 weeks) in adults with TRS. All datasets underwent a standardized analytic pipeline. Primary analyses were logistic regression of baseline NLR predicting response (≥20% symptom improvement) and correlation between change in NLR and change in symptoms. Study-level estimates were pooled using fixed-effects meta-analysis. Meta-regressions examined sex, age, race, baseline severity, and baseline NLR. People with lived experience were involved in the interpretation of the results.Findings: Ten trials contributed 593 participants (236 [39·8%] female; mean age 37·5 years [SD 3·8]; 281 [47·4%] African ancestry). Mean baseline PANSS total was 90·1 (SD 16·2), baseline NLR 1·66 (SD 0·34), and pooled response rate 48·1%. Higher baseline NLR predicted clozapine response (OR=1·26; 95% CI 1·02–1·55; p=0·03; I2=0%). Female sex was independently associated with response (OR=1·66; 95% CI 1·14–2·41; p=0·008). NLR decreased as symptoms improved (r=−0·11; 95% CI −0·19 to −0·03; p=0·01; I2=0%). No study-level covariates moderated either association and there was no evidence of publication bias.Interpretation: Clozapine may exert its antipsychotic effects in TRS partly through normalisation of a heightened inflammatory state. Pre-treatment NLR, already routinely available from mandatory baseline blood work, could support earlier and more targeted clozapine initiation and inform development of novel anti-inflammatory strategies for TRS.PanelResearch in contextEvidence before this studyConverging evidence suggests that treatment resistant schizophrenia (TRS) is characterized by immune dysregulation and altered neuroimmune activity. Clozapine is the only drug indicated for TRS, and it is associated with unique immune mediated off target effects (e.g., benign fever, myocarditis…) and animal model data indicating immunomodulatory effects. Small studies suggest that immune effects may mediate clozapine unique antipsychotic properties in TRS, but large-scale clinical data is lacking.Added value of this studyIn this large-scale individual participant data meta-analysis we show that a higher inflammation state indicated by greater neutrophil to lymphocyte ratio (NLR) is associated with greater odds of responding to clozapine and that as symptoms improve the NLR normalizes.
- 20 December 2025
- Published by Elsevier in Spanish Journal of Psychiatry and Mental Health
The overlooked women of IES Ramón y Cajal
- 20 December 2025
- Published by Elsevier in Spanish Journal of Psychiatry and Mental Health
The overlooked women of IES Ramón y Cajal
- 9 April 2025
- Published by Elsevier in The European Journal of Psychiatry
- Vol. 39 (3)
Hyperprolactinemia in drug-naïve first episode psychosis and its association with BDNF levels
- 9 April 2025
- Published by Elsevier in The European Journal of Psychiatry
- Vol. 39 (3)
Hyperprolactinemia in drug-naïve first episode psychosis and its association with BDNF levels
- Open Access
- 25 October 2024
- Published by Royal College of Psychiatrists in European Psychiatry
- Vol. 67 (1) , e73
Symptom profile in suicide attempters during the COVID-19 pandemic: Relationships with suicide outcomes
Background: Suicidal behavior constitutes a multi-cause phenomenon that may also be present in people without a mental disorder. This study aims to analyze suicidal behavior outcomes in a sample of attempters, from a symptom-based approach. Methods: The sample comprised 673 patients (72% female; M = 40.9 years) who attended a hospital emergency department due to a suicide attempt. A wide range of clinical factors (e.g., psychopathology symptoms, psychiatric diagnoses, impulsivity, acquired capability), was administered within 15 days after the index attempt. Nine psychopathology domains were explored to identify the profile of symptoms, using latent profile analysis. The relationship between the profile membership and suicide outcome (i.e., intensity of suicidal ideation, number of suicide behaviors, and medical injury derived from index attempt) was also studied, using linear and logistic regression. Results: Three psychopathology profiles were identified: high-symptom profile (45.02% of participants), moderate-symptom profile (42.50%), and low-symptom profile (12.48%). High-symptom profile members were more likely to show higher risk of non-suicidal self-injury, acquired capability for suicide, and more severe suicide behavior and ideation. On the other hand, a more severe physical injury was associated with low-symptom profile membership in comparison to membership from the other profiles (OR < 0.45, p < .05). Conclusions: A symptom-based approach may be useful to monitor patients and determine the risk of attempt repetition in the future and potential medical injury, and to optimize prevention and intervention strategies.
- 25 October 2024
- Published by Royal College of Psychiatrists in European Psychiatry
- Vol. 67 (1) , e73
Open AccessSymptom profile in suicide attempters during the COVID-19 pandemic: Relationships with suicide outcomes
Background: Suicidal behavior constitutes a multi-cause phenomenon that may also be present in people without a mental disorder. This study aims to analyze suicidal behavior outcomes in a sample of attempters, from a symptom-based approach. Methods: The sample comprised 673 patients (72% female; M = 40.9 years) who attended a hospital emergency department due to a suicide attempt. A wide range of clinical factors (e.g., psychopathology symptoms, psychiatric diagnoses, impulsivity, acquired capability), was administered within 15 days after the index attempt. Nine psychopathology domains were explored to identify the profile of symptoms, using latent profile analysis. The relationship between the profile membership and suicide outcome (i.e., intensity of suicidal ideation, number of suicide behaviors, and medical injury derived from index attempt) was also studied, using linear and logistic regression. Results: Three psychopathology profiles were identified: high-symptom profile (45.02% of participants), moderate-symptom profile (42.50%), and low-symptom profile (12.48%). High-symptom profile members were more likely to show higher risk of non-suicidal self-injury, acquired capability for suicide, and more severe suicide behavior and ideation. On the other hand, a more severe physical injury was associated with low-symptom profile membership in comparison to membership from the other profiles (OR < 0.45, p < .05). Conclusions: A symptom-based approach may be useful to monitor patients and determine the risk of attempt repetition in the future and potential medical injury, and to optimize prevention and intervention strategies.